BYSI - BeyondSpring Inc logo

BYSI

BeyondSpring Inc

Net income grew 100% of years5Y
Hold

BeyondSpring Inc. develops biopharmaceutical therapies focused on oncology, particularly its lead asset Plinabulin for non-small cell lung cancer and chemotherapy-induced neutropenia. The company also explores combinations with immuno-oncology agents.

โš•๏ธ Healthcare NASDAQ Listed 2017 $ USD
$1,000 invested 5 years ago โ†’$32today

Score Overview

1 Year
Scoreโ€”
Net Growth4.38%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Score6.1
Net Growth88.09%
Net TrendEvery year
Net Income Consistencyโ€”
Rev Growth-100.00%
Rev Trend20%
Revenue Consistencyโ€”
All Time
Scoreโ€”
Net Growth91.67%
Net Trend78%
Net Income Consistency
Rev Growthโ€”
Rev Trend33%
Revenue Consistency

See the full market ranking โ†’

BeyondSpring Inc fundamental performance

Between 2020 and 2025, revenue declined from $ 180K to $ 0.00 and net income went from -$ 60M to -$ 7M. Revenue increased in 1 of those 5 years; net income in every one.

BeyondSpring Inc currently holds a 5-year HDB Score of 6.1 out of 10. How the HDB Score is calculated.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 0.74โ€”
1 Year2025-08-12
$ 2.01-63.08%
5 Years2021-08-12
$ 23.18-96.80%
All Time2017-03-09
$ 16.80-95.58%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 0.00-$ 7M$ 7M
2025$ 0.00-$ 7M$ 12M
2024$ 0.00-$ 11M$ 2M
2023$ 1M-$ 21M$ 15M
2022$ 1M-$ 33M$ 37M
2021$ 1M-$ 64M$ 72M
2020$ 180K-$ 60M$ 109M
2019$ 0.00-$ 38M$ 35M
2018$ 0.00-$ 54M$ 3M
IPO2017$ 0.00-$ 91M$ 30M

Explore beyond BYSI

You're looking at BeyondSpring Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies